{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T15:24:12Z","timestamp":1787585052640,"version":"build-2736575974"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 82474374"],"award-info":[{"award-number":["No. 82474374"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-026-06711-8","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T14:33:16Z","timestamp":1787581996000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Global research landscape of benign prostatic hyperplasia (2010\u20132026): a bibliometric and visualized analysis revealing evolving trends, hotspots, and future frontiers"],"prefix":"10.1007","volume":"44","author":[{"given":"Qinghua","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingzhi","family":"Ran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danping","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinrong","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"key":"6711_CR1","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1080\/14656566.2023.2237406","volume":"24","author":"A Koudonas","year":"2023","unstructured":"Koudonas A, Anastasiadis A, Tsiakaras S, Langas G, Savvides E, Mykoniatis I et al (2023) Overview of current pharmacotherapeutic options in benign prostatic hyperplasia. Expert Opin Pharmacother 24:1609\u20131622","journal-title":"Expert Opin Pharmacother"},{"key":"6711_CR2","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/S0022-5347(01)63760-1","volume":"159","author":"JA Chicharro-Molero","year":"1998","unstructured":"Chicharro-Molero JA, Burgos-Rodriguez R, Sanchez-Cruz JJ, del Rosal-Samaniego JM, Rodero-Carcia P, Rodriguez-Vallejo JM (1998) Prevalence of benign prostatic hyperplasia in Spanish men 40 years old or older. J Urol 159:878\u2013882","journal-title":"J Urol"},{"key":"6711_CR3","doi-asserted-by":"publisher","first-page":"e754","DOI":"10.1016\/S2666-7568(22)00213-6","volume":"3","author":"The global","year":"2022","unstructured":"The global (2022) regional, and national burden of benign prostatic hyperplasia in 204 countries and territories from 2000 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Healthy Longev 3:e754\u2013e76","journal-title":"Lancet Healthy Longev"},{"key":"6711_CR4","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1186\/s12967-024-05604-x","volume":"22","author":"Z Song","year":"2024","unstructured":"Song Z, Cheng ZJ, Yuan H, Chang Z, Lv Y, Huang X et al (2024) Correlation between benign prostatic hyperplasia and comorbidities: a systematic analysis integrating global burden of disease and Mendelian randomization study. J Transl Med 22:1035","journal-title":"J Transl Med"},{"key":"6711_CR5","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1159\/000527792","volume":"107","author":"F Zhang","year":"2023","unstructured":"Zhang F, Xu J, Sun C, Dai F, Zhu Q, Liang H (2023) A scientometric visualization analysis for benign prostatic hyperplasia from 2016 to 2022. Urol Int 107:111\u2013125","journal-title":"Urol Int"},{"key":"6711_CR6","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.urology.2019.11.033","volume":"136","author":"A Paniagua Cruz","year":"2020","unstructured":"Paniagua Cruz A, Zhu KY, Ellimoottil C, Dauw CA, Sarma A, Skolarus TA (2020) Characterizing the benign prostatic hyperplasia literature: a bibliometric analysis. Urology 136:202\u2013211","journal-title":"Urology"},{"key":"6711_CR7","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s00345-026-06257-9","volume":"44","author":"A Tozsin","year":"2026","unstructured":"Tozsin A, Arslan E, Ermi\u015f O, Akg\u00fcl B, G\u00fcven S, Herrmann TR (2026) Characterizing the academic literature on surgical management of benign prostatic hyperplasia: a bibliometric analysis. World J Urol 44:159","journal-title":"World J Urol"},{"key":"6711_CR8","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1007\/s00345-020-03532-1","volume":"39","author":"AC Reichelt","year":"2021","unstructured":"Reichelt AC, Suarez-Ibarrola R, Herrmann TRW, Miernik A, Sch\u00f6b DS (2021) Laser procedures in the treatment of BPH: a bibliometric study. World J Urol 39:2903\u20132911","journal-title":"World J Urol"},{"key":"6711_CR9","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/s41419-025-07783-x","volume":"16","author":"J Li","year":"2025","unstructured":"Li J, Chen B, Huang Y, Liao X, You J, Chen Z et al (2025) TNF-\u03b1 modulates cell proliferation via SOX4\/TGF-\u03b2\/Smad signaling in benign prostatic hyperplasia. Cell Death Dis 16:472","journal-title":"Cell Death Dis"},{"key":"6711_CR10","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1097\/01.ju.0000127760.87421.e9","volume":"171","author":"R Taoka","year":"2004","unstructured":"Taoka R, Tsukuda F, Ishikawa M, Haba R, Kakehi Y (2004) Association of prostatic inflammation with down-regulation of macrophage inhibitory cytokine-1 gene in symptomatic benign prostatic hyperplasia. J Urol 171:2330\u20132335","journal-title":"J Urol"},{"key":"6711_CR11","doi-asserted-by":"publisher","first-page":"155798832614363","DOI":"10.1177\/15579883261436335","volume":"20","author":"W Gao","year":"2026","unstructured":"Gao W, Guo Y, Yu X, Zhang T, Gong H, Zhang Y (2026) The association between metabolic syndrome and benign prostatic hyperplasia: a systematic review and meta-analysis. Am J Men\u2019s Health 20:15579883261436335","journal-title":"Am J Men\u2019s Health"},{"key":"6711_CR12","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/s41585-025-01112-9","volume":"23","author":"Z Wang","year":"2026","unstructured":"Wang Z, Gu B, Sharkey C, Ge R, Olumi AF (2026) SRD5A2 and emerging therapies in androgen-driven disorders. Nat Rev Urol 23:319\u2013332","journal-title":"Nat Rev Urol"},{"key":"6711_CR13","doi-asserted-by":"publisher","first-page":"11116","DOI":"10.1038\/s41598-024-61977-5","volume":"14","author":"BT Yoosuf","year":"2024","unstructured":"Yoosuf BT, Panda AK, Kt MF, Bharti SK, Devana SK, Bansal D (2024) Comparative efficacy and safety of alpha-blockers as monotherapy for benign prostatic hyperplasia: a systematic review and network meta-analysis. Sci Rep 14:11116","journal-title":"Sci Rep"},{"key":"6711_CR14","doi-asserted-by":"crossref","unstructured":"Lv Z, Wang Y, Lv C, Lu Y, Cheng Q, Zhang H et al (2026) Global stagnation and misaligned priorities in BPH drug development: a 25-year landscape analysis of clinical trial registries. npj Aging 12:85","DOI":"10.1038\/s41514-026-00387-5"},{"key":"6711_CR15","first-page":"2","volume":"27","author":"AK Das","year":"2020","unstructured":"Das AK, Han TM, Uhr A, Roehrborn CG (2020) Benign prostatic hyperplasia: an update on minimally invasive therapy including aquablation. Can J Urol 27:2\u201310","journal-title":"Can J Urol"},{"key":"6711_CR16","first-page":"13","volume":"26","author":"AK Das","year":"2019","unstructured":"Das AK, Teplitsky S, Humphreys MR (2019) Holmium laser enucleation of the prostate (HoLEP): a review and update. Can J Urol 26:13\u201319","journal-title":"Can J Urol"},{"key":"6711_CR17","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1097\/JU.0000000000003483","volume":"210","author":"N Bhojani","year":"2023","unstructured":"Bhojani N, Bidair M, Kramolowsky E, Desai M, Doumanian L, Zorn KC et al (2023) Aquablation therapy in large prostates (80\u2013150 mL) for lower urinary tract symptoms due to benign prostatic hyperplasia: final WATER II 5-year clinical trial results. J Urol 210:143\u2013153","journal-title":"J Urol"},{"key":"6711_CR18","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/luts.12435","volume":"14","author":"M Babar","year":"2022","unstructured":"Babar M, Loloi J, Tang K, Syed U, Ciatto M (2022) Emerging outcomes of water vapor thermal therapy (Rezum) in a broad range of patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review. Lower urinary tract symptoms 14:140\u2013154","journal-title":"Lower urinary tract symptoms"},{"key":"6711_CR19","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/JU.0000000000003698","volume":"211","author":"JS Sandhu","year":"2024","unstructured":"Sandhu JS, Bixler BR, Dahm P, Goueli R, Kirkby E, Stoffel JT et al (2024) Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH): AUA guideline amendment 2023. J Urol 211:11\u201319","journal-title":"J Urol"},{"key":"6711_CR20","first-page":"590693","volume":"18","author":"E Aljazei","year":"2026","unstructured":"Aljazei E (2026) Artificial intelligence as a diagnostic tool for benign prostatic hyperplasia (BPH): a narrative review. Res Rep Urol 18:590693","journal-title":"Res Rep Urol"},{"key":"6711_CR21","first-page":"64","volume":"11","author":"H Zi","year":"2024","unstructured":"Zi H, Liu MY, Luo LS, Huang Q, Luo PC, Luan HH et al (2024) Global burden of benign prostatic hyperplasia, urinary tract infections, urolithiasis, bladder cancer, kidney cancer, and prostate cancer from 1990 to 2021. Mil Med Res 11:64","journal-title":"Mil Med Res"},{"key":"6711_CR22","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.urology.2022.03.008","volume":"166","author":"K Liu","year":"2022","unstructured":"Liu K, Yang J, Deng J, Fan X, Hu Y (2022) Global patent landscape of benign prostatic hyperplasia drugs. Urology 166:209\u2013215","journal-title":"Urology"},{"key":"6711_CR23","doi-asserted-by":"crossref","unstructured":"Mostafaei H, Salehi-Pourmehr H, Rahnama\u2019i MS, Mostafaei H, Shariat SF, Hajebrahimi S (2023) Microbiome in lower urinary tract symptoms (LUTSs): mapping the state of the art with bibliometric analysis. Life (Basel, Switzerland) 13:552","DOI":"10.3390\/life13020552"},{"key":"6711_CR24","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12894-025-02003-2","volume":"26","author":"Y Xu","year":"2026","unstructured":"Xu Y, An L, Xie J, Luo C, Huang X, Luo G (2026) The gut-prostate axis in benign prostatic hyperplasia: systematic review of microbial dysbiosis and pathogenic mechanisms. BMC Urol 26:26","journal-title":"BMC Urol"},{"key":"6711_CR25","doi-asserted-by":"publisher","first-page":"26152","DOI":"10.1038\/s41598-024-77515-2","volume":"14","author":"Y Cui","year":"2024","unstructured":"Cui Y, Wang H, Wang Y (2024) Plasma metabolites as mediators in the relationship between inflammation-related proteins and benign prostatic hyperplasia: insights from Mendelian randomization. Sci Rep 14:26152","journal-title":"Sci Rep"},{"key":"6711_CR26","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1007\/s00345-024-05379-2","volume":"43","author":"XD Lan","year":"2025","unstructured":"Lan XD, Yu ZY, Jiang R, Li ZC, Yang L, Zhang K et al (2025) Application trends and research hotspots of endoscopic enucleation of the prostate: a bibliometric and visualization analysis. World J Urol 43:140","journal-title":"World J Urol"},{"key":"6711_CR27","first-page":"6170","volume":"19","author":"NG Lee","year":"2012","unstructured":"Lee NG, Xue H, Lerner LB (2012) Trends and attitudes in surgical management of benign prostatic hyperplasia. Can J Urol 19:6170\u20136175","journal-title":"Can J Urol"},{"key":"6711_CR28","doi-asserted-by":"publisher","first-page":"153303382311550","DOI":"10.1177\/15330338231155000","volume":"22","author":"LV Sciacqua","year":"2023","unstructured":"Sciacqua LV, Vanzulli A, Di Meo R, Pellegrino G, Lavorato R, Vitale G et al (2023) Minimally invasive treatment in benign prostatic hyperplasia (BPH). Technol Cancer Res Treat 22:15330338231155000","journal-title":"Technol Cancer Res Treat"},{"key":"6711_CR29","doi-asserted-by":"publisher","first-page":"e14250","DOI":"10.1111\/ijcp.14250","volume":"75","author":"B Mi\u00f1ana","year":"2021","unstructured":"Mi\u00f1ana B, Molero JM, Agra Rol\u00e1n A, Mart\u00ednez-Fornes MT, Cuervo Pinto R, Lorite Mingot D et al (2021) Real-world therapeutic management and evolution of patients with benign prostatic hyperplasia in primary care and urology in Spain. Int J Clin Pract 75:e14250","journal-title":"Int J Clin Pract"},{"key":"6711_CR30","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1016\/j.juro.2011.01.074","volume":"185","author":"KT McVary","year":"2011","unstructured":"McVary KT, Roehrborn CG, Avins AL, Barry MJ, Bruskewitz RC, Donnell RF et al (2011) Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol 185:1793\u20131803","journal-title":"J Urol"},{"key":"6711_CR31","doi-asserted-by":"publisher","first-page":"3629","DOI":"10.1007\/s00345-023-04658-8","volume":"41","author":"D Liu","year":"2023","unstructured":"Liu D, Li C, Li Y, Zhou L, Li J, Wang Y et al (2023) Benign prostatic hyperplasia burden comparison between China and United States based on the Global Burden of Disease Study 2019. World J Urol 41:3629\u20133634","journal-title":"World J Urol"},{"key":"6711_CR32","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1111\/bju.15286","volume":"127","author":"BM Launer","year":"2021","unstructured":"Launer BM, McVary KT, Ricke WA, Lloyd GL (2021) The rising worldwide impact of benign prostatic hyperplasia. BJU Int 127:722\u2013728","journal-title":"BJU Int"},{"key":"6711_CR33","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.ucl.2025.07.007","volume":"52","author":"AE Te","year":"2025","unstructured":"Te AE, Kaplan SA (2025) Balloons in benign prostatic hyperplasia: will they float? A comprehensive review of prostatic balloon prostatoplasty. Urologic Clin North Am 52:559\u2013566","journal-title":"Urologic Clin North Am"},{"key":"6711_CR34","doi-asserted-by":"crossref","unstructured":"Te AE, Ramaswamy A, Kaplan SA (2026) Modern day cost analysis demonstrates medical therapy as a highly cost\u2013effective first\u2013line treatment for BPH\/LUTS. Prostate Cancer Prostatic Dis","DOI":"10.1038\/s41391-026-01089-5"},{"key":"6711_CR35","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1177\/08927790251412401","volume":"40","author":"J Fulla","year":"2026","unstructured":"Fulla J, Arroyave JS, Larenas F, Kaplan SA, Palese M, Sanchez C (2026) Impact of median lobe protrusion on outcomes of water vapor thermal therapy for benign prostatic hyperplasia: a prospective analysis. J Endourol 40:205\u2013211","journal-title":"J Endourol"},{"key":"6711_CR36","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1097\/JU.0000000000004896","volume":"215","author":"SA Kaplan","year":"2026","unstructured":"Kaplan SA, Parekattil SJ, Wu NZ, Mazzarella B, Trotter M, Freedman S et al (2026) 12-month outcomes from a randomized, sham-controlled trial evaluating a novel prostatic urethral stent for the treatment of benign prostatic hyperplasia. J Urol 215:421\u2013430","journal-title":"J Urol"},{"key":"6711_CR37","doi-asserted-by":"publisher","first-page":"e70156","DOI":"10.1002\/bco2.70156","volume":"7","author":"JD Cabral","year":"2026","unstructured":"Cabral JD, Gannon M, Raster G, Nusbaum DJ, Bouhadana D, Arezki A et al (2026) Outcomes of aquablation in BPH with bladder stones: analysis of the ICARUS database. BJUI Compass 7:e70156","journal-title":"BJUI Compass"},{"key":"6711_CR38","doi-asserted-by":"publisher","first-page":"175628722514149","DOI":"10.1177\/17562872251414925","volume":"18","author":"V Hou","year":"2026","unstructured":"Hou V, Vereecken SJ, Doersch KM, Zorn KC, Pohlman GD, Lloyd GL (2026) Modern approaches to BPH management: expert insights and the latest evidence from the 2024 International Functional and Reconstructive Urology update. Ther Adv Urol 18:17562872251414925","journal-title":"Ther Adv Urol"},{"key":"6711_CR39","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.urology.2026.04.009","volume":"212","author":"MHB Siqueira","year":"2026","unstructured":"Siqueira MHB, Buksh O, Hammoud A, Bhojani N, Meskawi M, Chughtai B et al (2026) The SUMMIT study: a real-world, clinical study to evaluate the performance of the Optilume BPH Catheter System in men with symptomatic benign prostatic hyperplasia. Urology 212:76\u201380","journal-title":"Urology"},{"key":"6711_CR40","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1007\/s00345-026-06232-4","volume":"44","author":"N Lee","year":"2026","unstructured":"Lee N, Benzouak T, Nguyen DD, Belliveau S, Murad L, Kadi L et al (2026) Membranous urethral length as a predictor for urinary incontinence after holmium enucleation of the prostate for benign prostatic hyperplasia. World J Urol 44:138","journal-title":"World J Urol"},{"key":"6711_CR41","doi-asserted-by":"publisher","first-page":"e70043","DOI":"10.1111\/luts.70043","volume":"18","author":"MHB Siqueira","year":"2026","unstructured":"Siqueira MHB, Shprits S, Bhojani N, Chughtai B, Zorn KC, Cindolo L et al (2026) Rez\u016bm therapy in very elderly men with BPH: two-year outcomes from a multicenter cohort. Lower Urinary Tract Symptoms 18:e70043","journal-title":"Lower Urinary Tract Symptoms"},{"key":"6711_CR42","doi-asserted-by":"crossref","unstructured":"Nicholson TM, Ricke WA (2011) Androgens and estrogens in benign prostatic hyperplasia: past, present and future. Differ Res Biol Divers 82:184\u2013199","DOI":"10.1016\/j.diff.2011.04.006"},{"key":"6711_CR43","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.juro.2018.05.048","volume":"200","author":"HE Foster","year":"2018","unstructured":"Foster HE, Barry MJ, Dahm P, Gandhi MC, Kaplan SA, Kohler TS et al (2018) Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline. J Urol 200:612\u2013619","journal-title":"J Urol"},{"key":"6711_CR44","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.ucl.2016.04.001","volume":"43","author":"KB Egan","year":"2016","unstructured":"Egan KB (2016) The epidemiology of benign prostatic hyperplasia associated with lower urinary tract symptoms: prevalence and incident rates. Urologic Clin North Am 43:289\u2013297","journal-title":"Urologic Clin North Am"},{"key":"6711_CR45","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.eururo.2011.03.055","volume":"60","author":"C De Nunzio","year":"2011","unstructured":"De Nunzio C, Kramer G, Marberger M, Montironi R, Nelson W, Schr\u00f6der F et al (2011) The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. Eur Urol 60:106\u2013117","journal-title":"Eur Urol"},{"key":"6711_CR46","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1111\/bju.12118","volume":"112","author":"G Gandaglia","year":"2013","unstructured":"Gandaglia G, Briganti A, Gontero P, Mondaini N, Novara G, Salonia A et al (2013) The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). BJU Int 112:432\u2013441","journal-title":"BJU Int"},{"key":"6711_CR47","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1111\/bju.12745","volume":"115","author":"M Speakman","year":"2015","unstructured":"Speakman M, Kirby R, Doyle S, Ioannou C (2015) Burden of male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH)\u2014focus on the UK. BJU Int 115:508\u2013519","journal-title":"BJU Int"},{"key":"6711_CR48","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1148\/radiol.10100021","volume":"257","author":"A Oto","year":"2010","unstructured":"Oto A, Kayhan A, Jiang Y, Tretiakova M, Yang C, Antic T et al (2010) Prostate cancer: differentiation of central gland cancer from benign prostatic hyperplasia by using diffusion-weighted and dynamic contrast-enhanced MR imaging. Radiology 257:715\u2013723","journal-title":"Radiology"},{"key":"6711_CR49","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/j.eururo.2012.02.033","volume":"61","author":"M Gacci","year":"2012","unstructured":"Gacci M, Corona G, Salvi M, Vignozzi L, McVary KT, Kaplan SA et al (2012) A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with \u03b1-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 61:994\u20131003","journal-title":"Eur Urol"},{"key":"6711_CR50","doi-asserted-by":"publisher","first-page":"1799399","DOI":"10.3389\/fmed.2026.1799399","volume":"13","author":"C Meng","year":"2026","unstructured":"Meng C, Peng L, Zeng Z, Wang Z, Ge S, Gan L et al (2026) Development and explainability of a machine learning prediction model for histological prostatic inflammation in surgically treated patients with benign prostatic hyperplasia: a single-center internal validation study. Front Med 13:1799399","journal-title":"Front Med"},{"key":"6711_CR51","doi-asserted-by":"crossref","unstructured":"Biesiadecki M, Galiniak S, Balawender K, Po\u0142e\u0107 J, Mo\u0142o\u0144 M (2026) Systemic oxidative and nitrosative stress in benign prostatic hyperplasia. Antioxid (Basel Switzerland) 15:488","DOI":"10.3390\/antiox15040488"},{"key":"6711_CR52","doi-asserted-by":"publisher","DOI":"10.64898\/2026.04.23.720409","volume-title":"Toxoplasma gondii associates with human benign prostatic hyperplasia and induces prostatic hyperplasia and accompanying urinary dysfunction in mice","author":"EF Stanczak","year":"2026","unstructured":"Stanczak EF, Fuller TD, Strand DW, Xia H, Strobel OR, Bermejo IH et al (2026) Toxoplasma gondii associates with human benign prostatic hyperplasia and induces prostatic hyperplasia and accompanying urinary dysfunction in mice. The Preprint Server for Biology, bioRxiv"},{"key":"6711_CR53","doi-asserted-by":"crossref","unstructured":"Davis KV, Thiess HM, Asbach P, Tiberi E, Denecke T, Hamm B et al (2026) Feasibility of multifrequency MR elastography of the seminal vesicles in healthy men, benign prostatic hyperplasia, and prostate cancer. Eur Radiol Exp 10:50","DOI":"10.1186\/s41747-026-00772-5"},{"key":"6711_CR54","doi-asserted-by":"crossref","unstructured":"Salehi M, Alaee M, Mousavi M, Panahi G, Goodarzi D, Amri J (2026) Salivary and serum microRNAs as noninvasive biomarkers for distinguishing prostate cancer from benign prostatic hyperplasia. Am J Clin Pathol 165:aqag028","DOI":"10.1093\/ajcp\/aqag028"},{"key":"6711_CR55","doi-asserted-by":"crossref","unstructured":"Amin AIA, Samhan LM, Zaidi ARZ, Ali Amin AI, Faroog Z, Almalki BSR et al (2026) Prevalence of benign prostatic hyperplasia and prostate cancer among men presenting with lower urinary tract symptoms at a tertiary referral hospital in Dar es Salaam, Tanzania: a retrospective cross-sectional study. J Clin Med 15:2914","DOI":"10.3390\/jcm15082914"},{"key":"6711_CR56","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1177\/10926429251393894","volume":"36","author":"D Perez","year":"2026","unstructured":"Perez D, Mamber A, Pasherstnik M, Koulikov D, Natsheh AE, Shenfeld OZ et al (2026) Aquablation for benign prostatic hyperplasia: a prospective study with comparative analysis of transurethral resection of the prostate and holmium laser enucleation. J Laparoendosc Adv Surg Tech Part A 36:11\u201317","journal-title":"J Laparoendosc Adv Surg Tech Part A"},{"key":"6711_CR57","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.2147\/CIA.S119241","volume":"11","author":"XY Wang","year":"2016","unstructured":"Wang XY, Zong HT, Zhang Y (2016) Efficacy and safety of prostate artery embolization on lower urinary tract symptoms related to benign prostatic hyperplasia: a systematic review and meta-analysis. Clin Interv Aging 11:1609\u20131622","journal-title":"Clin Interv Aging"},{"key":"6711_CR58","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12894-023-01397-1","volume":"24","author":"R Altman","year":"2024","unstructured":"Altman R, Ferreira R, Barragan C, Bhojani N, Lajkosz K, Zorn KC et al (2024) Comparing prostatic artery embolization to surgical and minimally invasive procedures for the treatment of benign prostatic hyperplasia: a systematic review and meta-analysis. BMC Urol 24:22","journal-title":"BMC Urol"},{"key":"6711_CR59","doi-asserted-by":"publisher","first-page":"49","DOI":"10.5534\/wjmh.250092","volume":"44","author":"BNH Shin","year":"2026","unstructured":"Shin BNH, Maksoud R, Tan S, Rhee H, Park HJ, Chung E (2026) Efficacy and tolerability outcomes of minimally invasive surgical treatments for benign prostatic hyperplasia: a random-effects network meta-analysis. World J Men\u2019s Health 44:49\u201363","journal-title":"World J Men\u2019s Health"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-026-06711-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-026-06711-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-026-06711-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T14:33:19Z","timestamp":1787581999000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-026-06711-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,24]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6711"],"URL":"https:\/\/doi.org\/10.1007\/s00345-026-06711-8","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,24]]},"assertion":[{"value":"26 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No ethical approval is required.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No human subjects or animals were involved in this study.","order":3,"name":"Ethics","label":"Research involving human participants and\/or animals","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No informed is required.","order":4,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"602"}}